Clinical Trials and Research

AbstractIntroduction: Sickle cell disease is an inherited red blood cells disorder which leads to oxidative stress and resulting in the disturbance of energy…

OverviewThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease. …

AbstractBackground: Sickle cell disease, a genetic blood disorder marked by vaso-occlusive crises and severe pain, presents a major global health challenge.…

Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an average of 85% of…

AbstractSickle cell-beta thalassemia, a compound heterozygous hemoglobinopathy, can be difficult to diagnose because clinical features and laboratory findings often…

AbstractBackground: Sickle cell disease is the most common genetic disorder in the world. It is a real public health problem in sub-Saharan Africa. Early screening…

Agios Pharmaceuticals will present Phase 3 trial results for mitapivat in sickle cell disease at EHA 2026.Quiver AI SummaryAgios Pharmaceuticals announced that…

Newer oral anticoagulants, or blood thinners, were linked to a lower risk of clinically relevant nonmajor bleeding than warfarin, an older blood thinner, in adults…

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through…

ABSTRACTErythrocytaphoresis or RBC exchange (RBCX) is a key intervention in the management of sickle cell anemia for both chronic prophylaxis and emergent clinical…